TY - JOUR
T1 - Current therapy of the pemphigus group
AU - Kasperkiewicz, Michael
AU - Schmidt, Enno
AU - Zillikens, Detlef
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.
AB - Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.
UR - http://www.scopus.com/inward/record.url?scp=83155160947&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2011.03.014
DO - 10.1016/j.clindermatol.2011.03.014
M3 - Journal articles
C2 - 22137231
AN - SCOPUS:83155160947
SN - 0738-081X
VL - 30
SP - 84
EP - 94
JO - Clinics in Dermatology
JF - Clinics in Dermatology
IS - 1
ER -
